CTNM CSO exercises options, sells 100 shares

Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported a small set of stock transactions.

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. Chief Scientific Officer Daniel S. Lorrain reported a small set of stock transactions. On February 19, 2026, he exercised stock options for 100 shares of Class A common stock and acquired those 100 shares at a price of $1.01 per share.

On the same date, he sold 100 shares of Class A common stock at a price of $16.00 per share in an open-market transaction. After these transactions, he held 156,052 shares of Class A common stock directly and 6,842 shares indirectly through his spouse. The filing notes the transactions were made under a Rule 10b5-1 trading plan adopted on September 23, 2025.

Insider Trade Summary

Exercise and Sale: 100 shares ($1K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Lorrain Daniel S.

Role Chief Scientific Officer

Sold 100 shs ($2K)

Approx. gross sale proceeds $2K

Approx. exercise cost $101.00

Approx. pre-tax spread $1K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	100	$0.00	$0.00
Exercise	Class A Common Stock	100	$1.01	$101.00
Sale	Class A Common Stock	100	$16.00	$2K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 75,430 contracts (Direct); Class A Common Stock — 156,052 shares (Direct); Class A Common Stock — 6,842 shares (Indirect, By Spouse)

Footnotes (2)

1. F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
2. F2. The stock options are fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CTNM executive Daniel S. Lorrain report?

Daniel S. Lorrain reported exercising options for 100 shares of Contineum Therapeutics Class A common stock and selling 100 shares in an open-market transaction on February 19, 2026, as disclosed in a Form 4 insider trading report.

At what prices did Daniel S. Lorrain transact Contineum Therapeutics (CTNM) shares?

Lorrain acquired 100 CTNM Class A common shares at $1.01 per share through an option exercise and sold 100 shares at $16.00 per share in an open-market transaction on February 19, 2026, according to the Form 4 filing.

How many Contineum Therapeutics (CTNM) shares does Daniel S. Lorrain own after the Form 4 transactions?

After the reported transactions, Lorrain directly owns 156,052 shares of CTNM Class A common stock and indirectly owns 6,842 additional shares through his spouse, as stated in the Form 4 ownership table.

Were Daniel S. Lorrain’s CTNM trades made under a 10b5-1 trading plan?

Yes. The Form 4 footnotes state that these transactions were executed under a Rule 10b5-1 trading plan adopted by Daniel S. Lorrain on September 23, 2025, which pre-schedules trades in advance.

What role does Daniel S. Lorrain hold at Contineum Therapeutics (CTNM)?

Daniel S. Lorrain serves as Chief Scientific Officer of Contineum Therapeutics, Inc. His position is disclosed in the Form 4, which identifies him as an officer rather than a director or 10% beneficial owner.

How is indirect ownership reported for Daniel S. Lorrain’s CTNM shares?

The Form 4 shows 6,842 CTNM Class A common shares as indirectly owned by Daniel S. Lorrain through his spouse. This is categorized as indirect ownership with the notation “By Spouse” in the ownership description.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lorrain Daniel S.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/19/2026		M(1)		100	A	$1.01	156,152	D
Class A Common Stock	02/19/2026		S(1)		100	D	$16	156,052	D
Class A Common Stock								6,842	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.01	02/19/2026		M(1)			100	(2)	02/24/2030	Class A Common Stock	100	$0	75,430	D

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The stock options are fully vested and exercisable.

	/s/ Peter Slover, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.